Eisai Co Ltd (4523.T)
23 Jun 2017
* Ewopharma says it will commercialise Halaven (eribulin mesylate) in nine countries within European Union and in two countries outside of EU
* Positive topline results of large phase 3 trial show Eisai's lenvatinib meets primary endpoint in unresectable hepatocellular carcinoma
ZURICH, Jan 16 The Swiss blue-chip SMI was seen opening 0.2 percent easier at 8,436 points on Monday, according to premarket indications by bank Julius Baer .
Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.